New Pill Box Possibilities; Super Monkey Moms; Science Seen

Front Page | New Pill Box Possibilities; Super Monkey Moms; Science Seen PhotoDisc GENE THERAPY | New Pill Box Possibilities "Take two genes and call me in the morning"--not exactly what one would expect a family doctor to say, but it could become a common prescription if a new "gene pill" pans out. James Hagstrom, vice president of Mirus, Madison, Wis., says "This technology would be extremely useful for wide ranging therapeutic applications." Hagstrom moderated a talk at the recent Kno

Written byMignon Fogarty
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

GENE THERAPY | New Pill Box Possibilities

"Take two genes and call me in the morning"--not exactly what one would expect a family doctor to say, but it could become a common prescription if a new "gene pill" pans out. James Hagstrom, vice president of Mirus, Madison, Wis., says "This technology would be extremely useful for wide ranging therapeutic applications." Hagstrom moderated a talk at the recent Knowledge Foundation conference.

To make a gene pill, researchers formulated DNA to survive the stomach's harsh environment and integrate into intestinal cells. Researcher David Olson, of Genteric, Alameda, Calif., which developed this new therapy, says that expression of a gene incorporated into intestinal cells would last about 10 days, because these cells undergo rapid turnover. Genteric showed that blood sugar dropped in diabetic mice that had received the human insulin gene via the gene pill.

Traditionally, such transient expression is a problem for ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies